Filing Details

Accession Number:
0001209191-21-005870
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-28 16:00:07
Reporting Period:
2021-01-26
Accepted Time:
2021-01-28 16:00:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1357874 Precision Biosciences Inc DTIL Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1769887 R. Matthew Kane C/O Precision Biosciences, Inc.
302 E. Pettigrew Street, Suite A-100
Durham NC 27701
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-26 21,515 $0.04 1,863,708 No 4 M Direct
Common Stock Disposition 2021-01-26 9,697 $13.37 1,854,011 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-01-26 21,515 $0.00 21,515 $0.04
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
258,168 2021-05-17 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,752 Indirect By Spouse
Footnotes
  1. All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.33 to $13.47. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Shares are held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. The option is fully vested and exercisable.